A fidget spinner for the point-of-care diagnosis of urinary tract infection

Michael, Issac J.; Kim, Dong‐Young; Gulenko, Oleksandra; Kumar, Sumit; Kumar, Sanjeev; Clara, Jothi; Ki, Dong Yeob; Park, Juhee; Jeong, Hyun Yong; Kim, Taek Soo; Kwon, Sunghoon; Cho, Yoon‐Kyoung

doi:10.1038/s41551-020-0557-2

Cited by 95 publications

(70 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this work, we responded to this call by implementing a versatile platform that can operate with multianalyte/sample tasks. A successful realization of either blood-based or non-invasive on-site monitoring of antibiotics using such a biosensor could be a game-changer in the antibiotherapy in the longer run and beyond since this technology could be extended to measure other drugs and biomarkers 40 . For instance, combining TDM of antibiotics and in ammation progress biomarkers could pave the way to personalized antibiotherapy.…”

Section: Discussionmentioning

confidence: 99%

Biosensor-enabled on-site therapeutic drug monitoring of antibiotics

Dincer

Ates

Mohsenin

et al. 2021

Preprint

View full text Add to dashboard Cite

Antimicrobial resistance is increasing with an alarming rate for which the prime suspect is the “one size-fits-all” dosage strategies of antibiotics. Personalized antibiotherapy framework appears as a viable option to counteract inadequate dosage, as it offers the application of the optimal dosage regimen for each individual. Such individualized scheme, however, needs frequent sampling to tailor the blood antibiotic concentration to respond unique pharmacokinetic/pharmacodynamic (PK/PD) of the patient. Herein, there are two alternative paths for feasible therapeutic drug monitoring (TDM); transforming our understanding to utilize blood based sampling within the scope of point-of-care (POC), or focusing on non-invasive samples. Here, we present a versatile biosensor along with an antibody-free assay that can be utilized in both paths for on-site TDM. The developed platform is evaluated in a large animal study (pigs exposed with overdose, normal dose, and underdose of ß lactams), in which antibiotic concentrations are quantified in matrices including whole blood, plasma, urine, saliva, and exhaled breath condensate (EBC). Herein, the detection and the clearance of drug concentrations in EBC is demonstrated for the first time. Influence of the secretion mechanisms on measured drug concentrations is then quantified by comparing the plasma concentrations with those in EBC, saliva and urine. The potential of the developed platform for blood-based POC application is further illustrated by tracking ß lactam concentrations in untreated blood samples. Finally, multiplexing capabilities are explored successfully for multianalyte/sample analysis. Enabling a rapid, low-cost, sample-independent, and multiplexed on-site TDM, this system could pave the way for the personalized drug therapies and thus, shift the paradigm of “one size-fits-all” strategies.

show abstract

Section: Discussionmentioning

confidence: 99%

Biosensor-enabled on-site therapeutic drug monitoring of antibiotics

Dincer

Ates

Mohsenin

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…In this regard, integration of the smartphones to sensors has brought new possibilities thanks to their enhanced imaging and computing capabilities, prevalent existence in the market, and familiarity for the end‐users as well as the technology developers. [ 78 ] Recent examples of this perspective are a hybrid device for the quantification of urine analytes, [ 79 ] the detection of bacterial infection via “fidget spinner” like lab‐on‐a‐disk platform, [ 80 ] and a fluorescence microarray for the detection of breast cancer‐specific biomarkers. [ 81 ] An alternative route to eliminate the need for an external readout for the quantitative analysis is the utilization of an integrated scale (for example, a ruler), as illustrated for the simultaneous detection of glucose and bovine serum albumin.…”

Section: Potential Of Non‐invasive Sampling In Integrated Devicesmentioning

confidence: 99%

Integrated Devices for Non‐Invasive Diagnostics

Ates

Brunauer

Stetten

et al. 2021

Adv Funct Materials

View full text Add to dashboard Cite

“Sample‐in‐answer‐out” type integrated diagnostic devices have been widely recognized as the ultimate solution to simplify testing across healthcare systems. Such systems are equipped with advanced fluidic, mechanical, chemical, biological, and electronic components to handle patient samples without any manual steps therefore have the potential to accelerate intervention and improve patient outcomes. In this regard, the combination of integrated devices and non‐invasive sampling has gained a substantial interest to further improve the comfort and safety of patients. In this Review, the pioneering developments in integrated diagnostics are covered and their potential in non‐invasive sampling is discussed. The key properties of possible sample types are highlighted by addressing their relevance for the clinical practice. Last, the factors affecting the transition of integrated devices from academia to the market are identified by analyzing the technology readiness levels of selected examples and alternative remedies are explored to increase the rate of survival during this transition.

show abstract

“…In resource-limited environments, the point-of-care identification of pathogens in biological samples needs to be rapid, simple, cost-effective, compact, precise. Michael et al [101] generated a custom-made fidget spinner based on Au NPs that rapidly concentrate the pathogens more than 100 times in 1 mL samples of undiluted urine for on-device colorimetric identification of bacterial loads and pathogen detection. The system allowed for the on-site, naked-eye identification of infection in urine samples from 39 patients suspected of having UTIs within 50 min.…”

Section: Diagnosis Of Utis By Nanotechnologymentioning

confidence: 99%

Nanomaterials for the Diagnosis and Treatment of Urinary Tract Infections

et al. 2021

View full text Add to dashboard Cite

The diagnosis and treatment of urinary tract infections (UTIs) remain challenging due to the lack of convenient assessment techniques and to the resistance to conventional antimicrobial therapy, showing the need for novel approaches to address such problems. In this regard, nanotechnology has a strong potential for both the diagnosis and therapy of UTIs via controlled delivery of antimicrobials upon stable, effective and sustained drug release. On one side, nanoscience allowed the production of various nanomaterial-based evaluation tools as precise, effective, and rapid procedures for the identification of UTIs. On the other side, nanotechnology brought tremendous breakthroughs for the treatment of UTIs based on the use of metallic nanoparticles (NPs) for instance, owing to the antimicrobial properties of metals, or of surface-tailored nanocarriers, allowing to overcome multidrug-resistance and prevent biofilm formation via targeted drug delivery to desired sites of action and preventing the development of cytotoxic processes in healthy cells. The goal of the current study is therefore to present the newest developments for the diagnosis and treatment of UTIs based on nanotechnology procedures in relation to the currently available techniques.

show abstract

A fidget spinner for the point-of-care diagnosis of urinary tract infection

Cited by 95 publications

References 39 publications

Biosensor-enabled on-site therapeutic drug monitoring of antibiotics

Biosensor-enabled on-site therapeutic drug monitoring of antibiotics

Integrated Devices for Non‐Invasive Diagnostics

Nanomaterials for the Diagnosis and Treatment of Urinary Tract Infections

Contact Info

Product

Resources

About